ClinicalTrials.gg
Status unknownNCT03468465SOLITENSUpdated Aug 2, 2018

Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome

A Phase 4 interventional study of Solifenacin Succinate and Neuro-Muscular Stimulators (NMS) in Urinary Incontinence, sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia. Status unknown at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-02.

Sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Phase 4, Interventional, and Other

How we know

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 56 studies in Urinary Incontinence with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Urinary Incontinence · Spain.

Planned enrollment
24th of 46
110 · median 113
Started
2018
with 1 other
Phase 4
4 of 56
none open now
Registered
25th of 56
by date

Among the 56 studies in Urinary Incontinence with a site in Spain, this one is the 24th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 4, and was the 25th registered.

Urinary Incontinence

986 studies on the registry are indexed under Urinary Incontinence; 183 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

12 of the 56 studies in Urinary Incontinence with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 110 Urinary Incontinence studies recruiting now, 61 (55%) set no upper age limit and 35 (32%) stop at 75 or younger; 15 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Urinary Incontinence with a site in Spain, or all of them as a file.
02

Study summary

  • To determine if the T-PTNS is not inferior in the short term (3 months) to one of the usual pharmacological treatments (Solifenacin) in the treatment of hyperactive bladder syndrome and with respect to the percentage of patients that improve 50% any of the 3 signs (Urinary frequency, diurnal / nocturnal frequency, urgency and urinary incontinence).
  • To determine prognostic factors associated with insufficient improvement (less than 50% in the 3 main signs of hyperactive bladder syndrome (urinary frequency, urgency and urinary incontinence frequency) after treatment with T-PTNS and Solifenacin.
Read the detailed description

Patients will be randomized to receive the usual standard treatment with Solifenacin or treatment based on peripheral unilateral transcutaneous neuromodulation of the posterior tibial nerve .

03

Conditions studied

  • Urinary Incontinence

Browse trials for

Keywords

  • Hyperactive Bladder Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women> 18 years, diagnosed with hyperactive bladder syndrome for at least 6 months of evolution and who have taken Beta 3 agonists

Exclusion criteria

Exclusion Criteria:

  • Patients who can contribute biased information: have previously consumed and abandoned anticholinergic drugs due to lack of efficacy or side effects; Suffering from hyperactive bladder of neurogenic origin (multiple sclerosis, Parkinson's, spinal cord injury); Present cystocele or any pelvic organ prolapse> 2 according to Pelvic Organ Prolapse-Q classification
  • Patients who may become worse with the interventions envisaged in the study: being a implantable automatic defibrillators; With cutaneous alterations in lower extremities that prevent the placement of electrodes on the surface; Women who are pregnant or who may be pregnant during the duration of the clinical trial (prior and at each evaluation visit urine Bhcg will be requested to rule out pregnancy) or patients who are not able to manage transcutaneous electrical neurostimulation on an outpatient basis ) Or patients in whom Solifenacin is : urinary retention, severe gastrointestinal disorders (including toxic megacolon), myasthenia gravis, or narrow-angle glaucoma, and in patients at risk of these conditions as hypersensitive at first Active or to any of the , undergoing hemodialysis, with moderate hepatic insufficiency or severe renal insufficiency or in simultaneous treatment with a potent inhibitor of , eg ketoconazole.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Medical device: Transcutaneous electrical neurostimulation

    Medical device 4 weeks with daily sessions of 30 minutes

    Device: Neuro-Muscular Stimulators (NMS)

  • Active comparator
    Solifenacin

    10 mg tablet daily during 75 days maximum

    Drug: Solifenacin Succinate

Interventions

  • DrugSolifenacinStudies of SolifenacinSolifenacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10 mg tablet daily during 75 days maximum

    Also known as: Vesicare

  • DeviceNeuro-Muscular Stimulators (NMS)

    Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period

    Also known as: T-PTNS

06

What researchers measure

Primary outcomes

  1. Evaluate whether treatment with T-PTNS is not less than 3 months compared to the current standard pharmacological treatments regarding the episodes of urgency, urinary frequency, incontinence and nocturia, all measured with the 3-day voiding diary

    3- day voiding diary

    Time frame: 12 weeks

07

Study locations

1 site
  • Hospital Clínico Universtario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Mar 2019, 10 months after the start.

Of 17 phase 4 interventional studies under Urinary Incontinence, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Mar 16, 2018
StartActual
May 4, 2018
Primary completionEst.
Mar 2019
CompletionEst.
Mar 2019
Last update
Aug 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03468465
Lead sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Responsible party
Sponsor
First posted
Mar 16, 2018
Start date
May 4, 2018
Primary completion
Mar 2019 (estimated)
Completion
Mar 2019 (estimated)
Last update
Aug 2, 2018

Study contacts

José David Jiménez Parra, MD
principal investigator · Hospital Rafael Méndez (Lorca, Murcia. SPAIN)
María Luisa María Luisa, MD
principal investigator · Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)
José Felix Escudero Bregante, MD
principal investigator · Hospital Clínico Universitario Virgen de la Arrixaca (SPAIN)
Julián Oñate, MD
principal investigator · Hospital General Universitario Reina Sofía (SPAIN)
Ana Isabel López López, MD
principal investigator · Hospital Clínico Universitario San Juan (SPAIN)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion